Point72 Discloses 4.73M Share Stake in Fate Therapeutics

TL;DR

**Point72 just bought 4.73M shares of FATE, big institutional bet!**

AI Summary

Point72 Asset Management, L.P. reported on January 24, 2024, that it beneficially owns 4,730,700 shares of Fate Therapeutics, Inc. common stock, representing a significant shared voting and dispositive power. This filing indicates a substantial investment by a major hedge fund in Fate Therapeutics, suggesting a potential vote of confidence in the biotech company's future. For investors, this means a large institutional player sees value, which could influence stock price and future sentiment.

Why It Matters

This filing reveals a major institutional investor, Point72 Asset Management, has taken a significant position in Fate Therapeutics, which can signal confidence and potentially attract other investors.

Risk Assessment

Risk Level: low — This filing indicates a large institutional investment, generally seen as a positive signal, reducing perceived risk.

Analyst Insight

A smart investor would research Fate Therapeutics, Inc.'s recent performance and future prospects, considering that a major hedge fund like Point72 Asset Management has taken a significant stake, potentially indicating an undervalued asset or strong growth potential.

Key Numbers

• 4,730,700 — Shares Beneficially Owned (Represents the total number of Fate Therapeutics shares Point72 Asset Management, L.P. has shared voting and dispositive power over.)
• $0.001 — Par Value per Share (The stated par value of Fate Therapeutics, Inc. Common Stock.)

Key Players & Entities

• Point72 Asset Management, L.P. (company) — the reporting person and institutional investor
• Fate Therapeutics, Inc. (company) — the subject company whose shares were acquired
• 03 Life Sciences (company) — organization name associated with Fate Therapeutics
• Delaware (company) — state of incorporation for Point72 Asset Management, L.P.
• January 24, 2024 (date) — date of event requiring the filing
• 4,730,700 (dollar_amount) — number of shares beneficially owned

Forward-Looking Statements

• Other institutional investors may increase their positions in Fate Therapeutics, Inc. following Point72's disclosure. (Fate Therapeutics, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• p24-0411sc13g.htm (SC 13G) — 74KB
• p24-0411exhibit99.htm (EX-99.1) — 8KB
• 0000902664-24-000657.txt ( ) — 83KB

(a)

Item 1(a). Name of Issuer. Fate Therapeutics, Inc. (the " Issuer ").

(b)

Item 1(b). Address of Issuer's Principal Executive Offices. 12278 Scripps Summit Drive, San Diego, CA 92131.

(a)

Item 2(a). Name of Person Filing. This statement is filed by: (i) Point72 Asset Management, L.P. (" Point72 Asset Management ") with respect to shares of common stock, par value $0.001 per share (" Shares "), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (" Point72 Capital Advisors Inc .") with respect to Shares held by an investment fund managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (" Cubist Systematic Strategies ") with respect to Shares held by an investment fund it manages; and (iv) Steven A. Cohen (" Mr. Cohen ") with respect to Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1 , pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

(b)

Item 2(b). Address of Principal Business Office. The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

(c)

Item 2(c). Place of Organization. Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company. Mr. Cohen is a United States citizen.

(d)

Item 2(d). Title of Class of Securities. Common Stock, par value $0.001 per share.

(e)

Item 2(e). CUSIP Number. 31189P102 Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a: Not applicable. CUSIP No. 31189P102 13G Page 7 of 8 Pages Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on January 24 2024. Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by a certain investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist Systematic Strategies maintains investment and voting power with respect to the securities held by an investment fund it manages. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein. Item 5. If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. See Item 2(a). Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable. Item

View Full Filing

View this SC 13G filing on SEC EDGAR